启明星 | Alamar正式落地亚太，香港神经退行性疾病中心实现ARGO HT首套装机｜B

日前，启明创投投资企业、努力于经由过程精准卵白质组学实现疾病晚期检测的公司Alamar Biosciences（下称“Alamar”）发布其寰球化过程的最新停顿：已在喷鼻港神经退行性疾病核心（“HKCeND”）装置了进步的超敏锐卵白质组学平台——ARGO™ HT体系。这是其在亚太地域实现的首套装机，标记着Alarma正式落地亚太地域。ARGO™ HT体系跟NULISA™技巧相联合，旨在经由过程史无前例的敏锐度跟正确性，使迷信家可能更好地检测跟定量卵白质，从而彻底改革生物标记物的发明进程。HKCeND装置培训现场Alamar与HKCeND的配合将专一于提醒阿尔茨海默病跟帕金森病等神经退行性疾病的分子机制跟由此带来的新看法。ARGO HT™跟NULISA™平台的安排将进一步加强HKCeND的研讨团队辨认新的生物标记物、减速药物开辟，并改良患者的晚期检测跟特性化医治战略的才能。Alamar Biosciences开创人、董事长兼CEO罗宇龄博士表现：“将ARGO™ HT体系装置到亚太地域，是咱们将冲破性卵白质组学处理计划带给寰球研讨者的愿景中的主要一步。咱们很愉快可能为HKCeND充斥活气的迷信社区做出奉献，并支撑其在应答神经退行性疾病方面获得更多的冲破性停顿。”喷鼻港神经退行性疾病核心主任叶玉如院士表现：“将ARGO™ HT体系及其支撑的NULISA™技巧整合到咱们的研讨基本设备中，是一项推翻性的改革。这项技巧将使得咱们可能以此前无奈设想的方法摸索神经退行性疾病的卵白质组学基本。”Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO™ HT Install at Hong Kong Center for Neurodegenerative DiseasesAlamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease and a portfolio company of Qiming Venture Partners, announces its commercial presence in the Asia Pacific (APAC) region with the installation of the ARGO™ HT System, an advanced ultra-sensitive proteomics platform, at the prestigious Hong Kong Center for Neurodegenerative Diseases (HKCeND). The ARGO™ HT System along with the NULISA™ Platform are designed to revolutionize biomarker discovery by enabling researchers to detect and quantify proteins at unprecedented levels of sensitivity and accuracy.The partnership with HKCeND will focus on unlocking new insights into the molecular mechanisms of neurodegenerative diseases such as Alzheimer's disease, and Parkinson's disease. The ARGO™ HT System and NULISA™ Platform deployments will empower HKCeND's researchers to identify novel biomarkers, accelerate drug development, and improve early detection and personalized treatment strategies for patients."Expansion of the ARGO™ HT installed base to the APAC region represents a significant step forward in our vision to bring transformative proteomics solutions to researchers worldwide," said Dr. Yuling Luo, Founder, Chairman and CEO of Alamar Biosciences. "We are excited to contribute to HKCeND's vibrant scientific community and support groundbreaking advancements in the fight against neurodegenerative diseases."Prof. Nancy Ip, the Director of Hong Kong Center for Neurodegenerative Diseases (HKCeND), added, "The integration of the NULISA™ Technology enabled by the ARGO™ HT System into our research infrastructure is a game-changer. This technology will allow us to explore the proteomic underpinnings of neurodegenerative diseases in ways that were previously unimaginable."往 期 回 顾]article_adlist-->启明星 | Alamar Biosciences 实现B轮融资8000万美元 ，启明创投持续投资 | Bilingual启明头条 | 2024启明创投医疗安康配合搭档开放日胜利举行，衔接寰球顶级药企与中国生物科技公司启明星 | 多家启明创投投资企业当选2024将来医疗科技引领者闪烁100及残暴100榜单启明创投建立于2006年。现在，启明创投旗下治理11只美元基金，7只国民币基金，已募治理资产总额到达95亿美元。自建立至今，专一于投资科技及花费(Technology and Consumer, T&C)、医疗安康(Healthcare)等行业晚期跟生长期的优良企业。停止现在，启明创投已投资超越580家高速生长的翻新企业，此中有超越210家分辨在美国纽交所、纳斯达克，喷鼻港买卖所，上交所及厚交所等买卖所上市，或经由过程并购等方法退出，有80多家企业成为行业公认的独角兽或超等独角兽企业。启明创投投资企业中，良多曾经生长为各自范畴中最具影响力的公司，包含小米团体（01810.HK）、美团（03690.HK）、哔哩哔哩（NASDAQ:BILI, 09626.HK）、知乎（NYSE:ZH, 02390.HK）、石头科技（688169.SH）、优必选（09880.HK）、文远知行（NASDAQ:WRD）、甘李药业（603087.SH）、泰格医药（300347.SZ, 03347.HK）、再鼎医药（NASDAQ:ZLAB, 09688.HK）、康希诺生物（688185.SH, 06185.HK）、Schrödinger（NASDAQ:SDGR）、惠泰医疗（688617.SH）、诺辉安康（06606.HK）、三友医疗（688085.SH）、艾德生物（300685.SZ）、贝瑞基因（000710.SZ）、神州细胞（688520.SH）、圆心科技、康缔亚、信心医药、壁仞科技等。]article_adlist-->（转自：启明创投） 　　申明：新浪网独家稿件，未经受权制止转载。 -->